Simoladagene autotemcel

N/A

Report date: 2023/01/12 15:52:06

Base Information

Drug NameSimoladagene autotemcel
Drug Alias NameADA gene therapy-Orchard TherapeuticsADA SCID gene therapy -Orchard TherapeuticsAutologous cryopreserved EFS-ADA LV CD34 cellsAutologous ex-vivo lentiviral adenosine deaminase gene therapy - Orchard TherapeuticsAdenosine deaminase gene therapy - Orchard Therapeutics +[8] 
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Source of cells > Leukocyte-derivedCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy +[5] 
Mechanisms of ActionAdenosine deaminase stimulantsGene transference
TargetsAdenosine deaminase
Therapy Area/IndicationsAdenosine deaminase deficiency
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesPctOrchard Therapeutics Plc
China Registration ClassN/A

Develop Information

Active CompaniesOrchard Therapeutics Plc
Inactive CompaniesUniversity Of California, Los Angeles
Active IndicationsAdenosine deaminase deficiency
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A